Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 217 articles: HTML format

Single Articles

November 2020
1. SOLIMAN H, Hogue D, Han HS, Mooney B, et al
   A phase 1 trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of non-metastatic triple-negative breast cancer.
   Clin Cancer Res. 2020 Nov 20. pii: 1078-0432.CCR-20-3105.
   PubMed     Abstract available
   
   
   
2. SHARMA P, Kimler BF, O'Dea AP, Nye L, et al
   Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP).
   Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-3646.
   PubMed     Abstract available
   
   
   
3. BALLINGER TJ, Jiang G, Kassem N, Radovich M, et al
   Impact of body mass index (BMI) on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple negative breast cancer: analysis from BRE12-158.
   Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3341.
   PubMed     Abstract available
   
   
   
4. GAO JJ, Osgood CL, Gong Y, Zhang H, et al
   FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer.
   Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3474.
   PubMed     Abstract available
   
   
   
5. NARAYAN P, Prowell TM, Gao JJ, Fernandes LL, et al
   FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.
   Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3652.
   PubMed     Abstract available
   
   
   
6. WAHBY S, Fashoyin-Aje L, Osgood CL, Cheng J, et al
   FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC).
   Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3119.
   PubMed     Abstract available
   
   
   
7. ANDREASSEN MMS, Rodriguez-Soto AE, Conlin CC, Vidic I, et al
   Discrimination of breast cancer from healthy breast tissue using a three-component diffusion-weighted MRI model.
   Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-2017.
   PubMed     Abstract available
   
   
   
8. STENMARK TULLBERG A, Puttonen HAJ, Sjostrom M, Holmberg E, et al
   Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial.
   Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-3299.
   PubMed     Abstract available
   
   
   October 2020
9. COLLINS DM, Madden SF, Gaynor N, AlSultan D, et al
   Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer.
   Clin Cancer Res. 2020 Oct 29. pii: 1078-0432.CCR-20-2007.
   PubMed     Abstract available
   
   
   
10. BALLHAUSEN A, Wheler JJ, Karp DD, Piha-Paul SA, et al
    Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors.
    Clin Cancer Res. 2020 Oct 28. pii: 1078-0432.CCR-20-2878.
    PubMed     Abstract available
    
    
    
11. NOORDHOEK I, Treuner K, Putter H, Zhang Y, et al
    Breast Cancer Index predicts extended endocrine benefit to individualize selection of HR+ early stage breast cancer patients for 10 years of endocrine therapy.
    Clin Cancer Res. 2020 Oct 27. pii: 1078-0432.CCR-20-2737.
    PubMed     Abstract available
    
    
    
12. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed     Abstract available
    
    
    
13. SHAH M, Wedam S, Cheng J, Fiero MH, et al
    FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Oct 14. pii: 1078-0432.CCR-20-2701.
    PubMed     Abstract available
    
    
    
14. LEE HB, Lee SB, Kim M, Kwon S, et al
    Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2107.
    PubMed     Abstract available
    
    
    
15. SCHROTH W, Buttner FA, Kandabarau S, Hoppe R, et al
    Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
    Clin Cancer Res. 2020 Oct 2. pii: 1078-0432.CCR-20-1923.
    PubMed     Abstract available
    
    
    September 2020
16. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed     Abstract available
    
    
    
17. KROP I, Abramson VG, Colleoni M, Traina TA, et al
    A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-1693.
    PubMed     Abstract available
    
    
    
18. PRAT A, Tsai YH, Pascual T, Pare L, et al
    A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.
    Clin Cancer Res. 2020 Sep 22. pii: 1078-0432.CCR-20-2793.
    PubMed     Abstract available
    
    
    
19. RICHARD F, Majjaj S, Venet D, Rothe F, et al
    Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2268.
    PubMed     Abstract available
    
    
    
20. CIRUELOS EM, Villagrasa P, Pascual T, Oliveira M, et al
    Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial.
    Clin Cancer Res. 2020 Sep 16. pii: 1078-0432.CCR-20-0844.
    PubMed     Abstract available
    
    
    
21. CHAN N, Willis A, Kornhauser N, Ward MM, et al
    Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
    Clin Cancer Res. 2020;26:5051.
    PubMed    
    
    
    
22. TOLANEY SM, Im YH, Calvo E, Lu YS, et al
    Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-0645.
    PubMed     Abstract available
    
    
    August 2020
23. HUNTER NB, Kilgore MR, Davidson NE
    The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.
    Clin Cancer Res. 2020 Aug 28. pii: 1078-0432.CCR-20-2451.
    PubMed     Abstract available
    
    
    
24. GUARNERI V, Dieci MV, Bisagni G, Brandes AA, et al
    PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
    Clin Cancer Res. 2020 Aug 25. pii: 1078-0432.CCR-20-1731.
    PubMed     Abstract available
    
    
    
25. AXELROD ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, et al
    Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer.
    Clin Cancer Res. 2020 Aug 21. pii: 1078-0432.CCR-19-3685.
    PubMed     Abstract available
    
    
    July 2020
26. CROSBY EJ, Acharya CR, Haddad AF, Rabiola CA, et al
    Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and alphaPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
    Clin Cancer Res. 2020 Jul 30. pii: 1078-0432.CCR-20-0389.
    PubMed     Abstract available
    
    
    
27. MAO P, Cohen O, Kowalski KJ, Kusiel J, et al
    Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-19-3958.
    PubMed     Abstract available
    
    
    
28. LU YS, Lee KS, Chao TY, Tseng LM, et al
    A Phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer.
    Clin Cancer Res. 2020 Jul 27. pii: 1078-0432.CCR-20-1008.
    PubMed     Abstract available
    
    
    
29. AHMED FS, Gaule P, McGuire J, Patel KK, et al
    PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab in triple negative breast cancer (TNBC).
    Clin Cancer Res. 2020 Jul 24. pii: 1078-0432.CCR-20-1303.
    PubMed     Abstract available
    
    
    
30. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available
    
    
    June 2020
31. MAGBANUA MJM, Savenkov O, Asmus EJ, Ballman K, et al
    Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab.
    Clin Cancer Res. 2020 Jun 25. pii: 1078-0432.CCR-20-1329.
    PubMed     Abstract available
    
    
    
32. VIDULA N, Dubash TD, Lawrence MS, Simoneau A, et al
    Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    Clin Cancer Res. 2020 Jun 22. pii: 1078-0432.CCR-20-0638.
    PubMed     Abstract available
    
    
    
33. SESTAK I, Filipits M, Buus R, Rudas M, et al
    Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-0260.
    PubMed     Abstract available
    
    
    
34. BAGO-HORVATH Z, Rudas M, Singer CF, Greil R, et al
    Predictive value of molecular subtypes in premenopausal women with hormone receptor-positive early breast cancer: Results from the ABCSG Trial 5.
    Clin Cancer Res. 2020 Jun 16. pii: 1078-0432.CCR-20-0673.
    PubMed     Abstract available
    
    
    
35. TURNER NC, Swift C, Kilburn LS, Fribbens C, et al
    ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials.
    Clin Cancer Res. 2020 Jun 16. pii: 1078-0432.CCR-20-0224.
    PubMed     Abstract available
    
    
    
36. LISCHKA A, Doberstein N, Freitag-Wolf S, Kocak A, et al
    Genome instability profiles predict disease outcome in a cohort of 4,003 breast cancer patients.
    Clin Cancer Res. 2020 Jun 10. pii: 1078-0432.CCR-20-0566.
    PubMed     Abstract available
    
    
    April 2020
37. HAMPSCH RA, Wells JD, Traphagen NA, McCleery CF, et al
    AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-20-0269.
    PubMed     Abstract available
    
    
    
38. SMYTH LM, Tamura K, Oliveira M, Ciruelos EM, et al
    Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2020 Apr 20. pii: 1078-0432.CCR-19-3953.
    PubMed     Abstract available
    
    
    
39. WHITTLE JR, Vaillant F, Surgenor E, Policheni AN, et al
    Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer.
    Clin Cancer Res. 2020 Apr 3. pii: 1078-0432.CCR-19-1872.
    PubMed     Abstract available
    
    
    
40. GILANI RA, Phadke S, Bao LW, Lachacz EJ, et al
    Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Clin Cancer Res. 2020;26:1777.
    PubMed    
    
    
    March 2020
41. ROBERTSON JF, Evans A, Henschen S, Kirwan CC, et al
    A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-19-3387.
    PubMed     Abstract available
    
    
    
42. GRIS-OLIVER A, Palafox M, Monserrat L, Braso-Maristany F, et al
    Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-3324.
    PubMed     Abstract available
    
    
    
43. WEDAM S, Fashoyin-Aje L, Gao X, Bloomquist E, et al
    FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer.
    Clin Cancer Res. 2020 Mar 26. pii: 1078-0432.CCR-19-3980.
    PubMed     Abstract available
    
    
    
44. PARSONS HA, Rhoades J, Reed SC, Gydush G, et al
    Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer.
    Clin Cancer Res. 2020 Mar 13. pii: 1078-0432.CCR-19-3005.
    PubMed     Abstract available
    
    
    February 2020
45. INGLE JN, Cairns J, Suman VJ, Shepherd LE, et al
    Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor alpha.
    Clin Cancer Res. 2020 Feb 25. pii: 1078-0432.CCR-19-3091.
    PubMed     Abstract available
    
    
    
46. CLIFTON GTT, Hale D, Vreeland TJ, Hickerson AT, et al
    Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2741.
    PubMed     Abstract available
    
    
    
47. SANTA-MARIA CA, Coughlin JW, Sharma D, Armanios M, et al
    The Effects of a Remote-Based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2935.
    PubMed     Abstract available
    
    
    
48. SPRING LM, Fell G, Arfe A, Sharma C, et al
    Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-3492.
    PubMed     Abstract available
    
    
    
49. BRANDAO M, Caparica R, Malorni L, Prat A, et al
    What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-2612.
    PubMed     Abstract available
    
    
    
50. BLAES AH, Domingo-Musibay E, Kalinsky K
    Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
    Clin Cancer Res. 2020 Feb 6. pii: 1078-0432.CCR-19-3818.
    PubMed     Abstract available
    
    
    
51. BARROSO-SOUSA R, Keenan TE, Pernas S, Exman P, et al
    Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-19-3507.
    PubMed     Abstract available
    
    
    
52. HUTCHINSON KE, Yost SE, Chang CW, Johnson RM, et al
    Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
    Clin Cancer Res. 2020;26:657-668.
    PubMed     Abstract available
    
    
    January 2020
53. ASLEH K, Brauer HA, Sullivan A, Lauttia S, et al
    Predictive biomarkers for adjuvant capecitabine benefit in early stage triple negative breast cancer in the FinXX clinical trial.
    Clin Cancer Res. 2020 Jan 31. pii: 1078-0432.CCR-19-1945.
    PubMed     Abstract available
    
    
    
54. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available
    
    
    
55. 
    Selected Articles from This Issue.
    Clin Cancer Res. 2020;26:323.
    PubMed    
    
    
    
56. MCCARTNEY A, Bonechi M, De Luca F, Biagioni C, et al
    Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-3271.
    PubMed     Abstract available
    
    
    
57. KARN T, Meissner T, Weber K, Solbach C, et al
    A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial.
    Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-19-1954.
    PubMed     Abstract available
    
    
    
58. BAM R, Lown PS, Stern LA, Sharma K, et al
    Efficacy of affibody-based ultrasound molecular imaging of vascular B7-H3 for breast cancer detection.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-1655.
    PubMed     Abstract available
    
    
    
59. POWLES RL, Wali VB, Li X, Barlow WE, et al
    Analysis of pre- and post-treatment tissues from the SWOG S0800 trial reveals an effect of neoadjuvant chemotherapy on the breast cancer genome.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-2405.
    PubMed     Abstract available
    
    
    
60. BYUN JS, Singhal S, Park S, Yi DI, et al
    Racial Differences in the Association between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.
    Clin Cancer Res. 2020 Jan 7. pii: 1078-0432.CCR-19-0875.
    PubMed     Abstract available
    
    
    December 2019
61. CHEN G, Ding X, Pressley K, Bouamar H, et al
    Everolimus inhibits the progression of ductal carcinoma in situ to invasive breast cancer via downregulation of MMP9 expression.
    Clin Cancer Res. 2019 Dec 23. pii: 1078-0432.CCR-19-2478.
    PubMed     Abstract available
    
    
    
62. LIU S, Gonzalez Prieto R, Zhang M, Geurink PP, et al
    Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFbeta-induced breast cancer metastasis.
    Clin Cancer Res. 2019 Dec 19. pii: 1078-0432.CCR-19-1373.
    PubMed     Abstract available
    
    
    
63. LI Q, Wang Y, Jia W, Deng H, et al
    Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade.
    Clin Cancer Res. 2019 Dec 17. pii: 1078-0432.CCR-19-2179.
    PubMed     Abstract available
    
    
    
64. SIMS AH, Leggate M, Campbell A
    Exercise Window Trial in Newly Diagnosed Breast Cancer-Letter.
    Clin Cancer Res. 2019;25:7609-7610.
    PubMed    
    
    
    
65. ROBERTSON JF, Coleman RE, Cheung KL, Evans A, et al
    Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT).
    Clin Cancer Res. 2019 Dec 13. pii: 1078-0432.CCR-19-3053.
    PubMed     Abstract available
    
    
    
66. PAGE DB, Pucilowska J, Sanchez KG, Conlin AK, et al
    A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1119.
    PubMed     Abstract available
    
    
    
67. LEHMANN BD, Abramson VG, Sanders M, Mayer EL, et al
    TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
    Clin Cancer Res. 2019 Dec 10. pii: 1078-0432.CCR-19-2170.
    PubMed     Abstract available
    
    
    
68. TELLI ML, Chu C, Badve SS, Vinayak S, et al
    Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-0664.
    PubMed     Abstract available
    
    
    
69. SAVAS P, Loi S
    Metastatic Breast Cancer: TIL it's too late.
    Clin Cancer Res. 2019 Dec 2. pii: 1078-0432.CCR-19-3490.
    PubMed     Abstract available
    
    
    November 2019
70. COBLEIGH M, Yardley D, Brufsky AM, Rugo HS, et al
    Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status From SystHERs.
    Clin Cancer Res. 2019 Nov 26. pii: 1078-0432.CCR-19-2350.
    PubMed     Abstract available
    
    
    
71. KNUTSON KL, Block MS, Norton N, Erskine CL, et al
    Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine.
    Clin Cancer Res. 2019 Nov 22. pii: 1078-0432.CCR-19-2123.
    PubMed     Abstract available
    
    
    
72. HILLER JG, Cole SW, Crone EM, Byrne DJ, et al
    Pre-operative beta-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2641.
    PubMed     Abstract available
    
    
    
73. WANG F, Reid S, Zheng W, Pal T, et al
    Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
    Clin Cancer Res. 2019 Nov 20. pii: 1078-0432.CCR-19-2424.
    PubMed     Abstract available
    
    
    
74. CHITALIA R, Rowland J, McDonald ES, Pantalone L, et al
    Imaging phenotypes of breast cancer heterogeneity in pre-operative breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) scans predict 10-year recurrence.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-4067.
    PubMed     Abstract available
    
    
    October 2019
75. RIMAWI MF, Niravath P, Wang T, Rexer BN, et al
    TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer.
    Clin Cancer Res. 2019 Oct 29. pii: 1078-0432.CCR-19-0851.
    PubMed     Abstract available
    
    
    
76. DE ANGELIS C, Nagi C, Hoyt CC, Liu L, et al
    Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy.
    Clin Cancer Res. 2019 Oct 25. pii: 1078-0432.CCR-19-1402.
    PubMed     Abstract available
    
    
    
77. WEDAM S, Fashoyin-Aje L, Bloomquist E, Tang S, et al
    FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2019 Oct 24. pii: 1078-0432.CCR-19-2580.
    PubMed     Abstract available
    
    
    
78. HAMMERL D, Massink MPG, Smid M, van Deurzen CHM, et al
    Clonality, antigen recognition and suppression of CD8+ T cells differentially affect prognosis of breast cancer subtypes.
    Clin Cancer Res. 2019 Oct 24. pii: 1078-0432.CCR-19-0285.
    PubMed     Abstract available
    
    
    
79. HUI R, Pearson A, Cortes J, Campbell C, et al
    Lucitanib for the treatment of HR(+)/ HER2(-) metastatic breast cancer: results from the multicohort phase II FINESSE study.
    Clin Cancer Res. 2019 Oct 16. pii: 1078-0432.CCR-19-1164.
    PubMed     Abstract available
    
    
    
80. HURVITZ SA, Martin M, Press MF, Chan D, et al
    Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.
    Clin Cancer Res. 2019 Oct 15. pii: 1078-0432.CCR-19-1425.
    PubMed     Abstract available
    
    
    
81. QUINTELA-FANDINO M, Morales S, Cortes-Salgado A, Manso L, et al
    Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.
    Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-2023.
    PubMed     Abstract available
    
    
    
82. PEARSON A, Proszek PZ, Pascual J, Fribbens C, et al
    Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance.
    Clin Cancer Res. 2019 Oct 7. pii: 1078-0432.CCR-18-4044.
    PubMed     Abstract available
    
    
    
83. YANG Y, Yang H, Tang B, Wu AML, et al
    The outcome of TGFbeta antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFbeta.
    Clin Cancer Res. 2019 Oct 3. pii: 1078-0432.CCR-19-2370.
    PubMed     Abstract available
    
    
    
84. PEGRAM MD, Miles D, Tsui CK, Zong Y, et al
    HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors.
    Clin Cancer Res. 2019 Oct 3. pii: 1078-0432.CCR-18-1976.
    PubMed     Abstract available
    
    
    September 2019
85. LEE O, Sullivan ME, Xu Y, Rodgers C, et al
    Selective progesterone receptor modulators in early stage breast cancer: a randomized, placebo-controlled Phase II window of opportunity trial using telapristone acetate.
    Clin Cancer Res. 2019 Sep 30. pii: 1078-0432.CCR-19-0443.
    PubMed     Abstract available
    
    
    
86. SJOSTROM M, Chang SL, Fishbane N, Davicioni E, et al
    ---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1038.
    PubMed     Abstract available
    
    
    
87. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    PubMed     Abstract available
    
    
    
88. LEAL MF, Haynes BP, Schuster EF, Yeo B, et al
    Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1129.
    PubMed     Abstract available
    
    
    
89. FINN RS, Liu Y, Zhu Z, Martin M, et al
    Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naive Metastatic Breast Cancer.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-0751.
    PubMed     Abstract available
    
    
    
90. HAMY AS, Bonsang-Kitzis H, De Croze D, Laas E, et al
    Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-18-3017.
    PubMed     Abstract available
    
    
    
91. HE X, Ji J, Tian M, Esteva FJ, et al
    Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-0463.
    PubMed     Abstract available
    
    
    
92. KOELWYN GJ, Jones LW
    Exercise as a Candidate Antitumor Strategy: A Window into the Future.
    Clin Cancer Res. 2019;25:5179-5181.
    PubMed     Abstract available
    
    
    August 2019
93. BAIRD RD, van Rossum AG, Oliveira M, Beelen KJ, et al
    POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0508.
    PubMed     Abstract available
    
    
    
94. WALSH L, Haley KE, Moran B, Mooney B, et al
    BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-0713.
    PubMed     Abstract available
    
    
    
95. YANG H, Shu Z, Jiang Y, Mao W, et al
    6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Clin Cancer Res. 2019 Aug 7. pii: 1078-0432.CCR-18-3448.
    PubMed     Abstract available
    
    
    
96. DRAGO JZ, Formisano L, Juric D, Niemierko A, et al
    FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0138.
    PubMed     Abstract available
    
    
    July 2019
97. PAOLETTI C, Miao J, Dolce EM, Darga EP, et al
    Circulating Tumor Cell Clusters in Metastatic Breast Cancer Patients: a SWOG S0500 Translational Medicine Study.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-19-0208.
    PubMed     Abstract available
    
    
    
98. ZHANG X, Zhao W, Wei W, You Z, et al
    Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Clin Cancer Res. 2019 Jul 26. pii: 1078-0432.CCR-18-4055.
    PubMed     Abstract available
    
    
    
99. DIHGE L, Vallon-Christersson J, Hegardt C, Saal LH, et al
    Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population based cohort.
    Clin Cancer Res. 2019 Jul 24. pii: 1078-0432.CCR-19-0075.
    PubMed     Abstract available
    
    
    
100. DOWNS B, Mercado-Rodriguez C, Cimino-Mathews A, Chen C, et al
     DNA Methylation Markers for Breast Cancer Detection in the Developing World.
     Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-18-3277.
     PubMed     Abstract available
     
     
     June 2019
101. MATIKAS A, Zerdes I, Lovrot J, Richard F, et al
     Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data.
     Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-1131.
     PubMed     Abstract available
     
     
     
102. CHEN J, Haanpaa MK, Gruber JJ, Jager N, et al
     High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
     Clin Cancer Res. 2019 Jun 7. pii: 1078-0432.CCR-18-2423.
     PubMed     Abstract available
     
     
     May 2019
103. MAGBANUA MJM, Yau C, Wolf DM, Lee JS, et al
     Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predict adverse outcome in early breast cancer.
     Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3888.
     PubMed     Abstract available
     
     
     
104. LI Q, Guan X, Chen S, Yi Z, et al
     Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
     Clin Cancer Res. 2019 May 28. pii: 1078-0432.CCR-18-4173.
     PubMed     Abstract available
     
     
     
105. STEENBRUGGEN TG, van Seijen M, Janssen LM, van Ramshorst MS, et al
     Prognostic value of residual disease after neoadjuvant therapy in HER2+ breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore.
     Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-19-0560.
     PubMed     Abstract available
     
     
     
106. FILIPITS M, Dubsky P, Rudas M, Greil R, et al
     Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
     Clin Cancer Res. 2019 May 7. pii: 1078-0432.CCR-19-0376.
     PubMed     Abstract available
     
     
     
107. MOLINA-CRESPO A, Cadete A, Sarrio D, Gamez-Chiachio M, et al
     Intracellular delivery of an antibody targeting Gasdermin-B reduces HER2 breast cancer aggressiveness.
     Clin Cancer Res. 2019 May 7. pii: 1078-0432.CCR-18-2381.
     PubMed     Abstract available
     
     
     
108. WAKS AG, Stover DG, Guerriero JL, Dillon DA, et al
     The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy.
     Clin Cancer Res. 2019 May 6. pii: 1078-0432.CCR-19-0173.
     PubMed     Abstract available
     
     
     
109. MEIJER TG, Verkaik NS, Sieuwerts AM, van Riet J, et al
     Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
     Clin Cancer Res. 2019;25:2935.
     PubMed    
     
     
     April 2019
110. MITTENDORF EA, Lu B, Melisko M, Price Hiller J, et al
     Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
     Clin Cancer Res. 2019 Apr 29. pii: 1078-0432.CCR-18-2867.
     PubMed     Abstract available
     
     
     
111. LIGIBEL J, Dillon DA, Giobbie-Hurder A, McTiernan A, et al
     Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: Results from the Pre-Operative Health and Body (PreHAB) Study.
     Clin Cancer Res. 2019 Apr 24. pii: 1078-0432.CCR-18-3143.
     PubMed     Abstract available
     
     
     
112. ZHANG J, Chen J, Wo D, Yan H, et al
     LRP6 ectodomain prevents SDF-1/CXCR4-induced breast cancer metastasis to lung.
     Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3557.
     PubMed     Abstract available
     
     
     
113. COOMBES C, Page K, Salari R, Hastings RK, et al
     Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.
     Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-3663.
     PubMed     Abstract available
     
     
     
114. MORIKAWA A, de Stanchina E, Pentsova E, Kemeny MM, et al
     Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases.
     Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-3502.
     PubMed     Abstract available
     
     
     
115. LOIBL S, Treue D, Budczies J, Weber K, et al
     Mutational diversity and therapy response in breast cancer - a sequencing analysis in the neoadjuvant GeparSepto trial.
     Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3258.
     PubMed     Abstract available
     
     
     March 2019
116. KRAYA AA, Maxwell KN, Wubbenhorst B, Wenz BM, et al
     Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer.
     Clin Cancer Res. 2019 Mar 26. pii: 1078-0432.CCR-18-0468.
     PubMed     Abstract available
     
     
     
117. KETTNER NM, Vijayaraghavan S, Durak MG, Bui T, et al
     Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer.
     Clin Cancer Res. 2019 Mar 13. pii: 1078-0432.CCR-18-3274.
     PubMed     Abstract available
     
     
     
118. ROTHE F, Silva MJ, Venet D, Campbell C, et al
     Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial.
     Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-2521.
     PubMed     Abstract available
     
     
     
119. SJOBERG E, Meyrath M, Milde L, Herrera M, et al
     A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer.
     Clin Cancer Res. 2019 Mar 8. pii: 1078-0432.CCR-18-1294.
     PubMed     Abstract available
     
     
     
120. LIU Z, Li Z, Qu J, Zhang R, et al
     Radiomics of multi-parametric MRI for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
     Clin Cancer Res. 2019 Mar 6. pii: 1078-0432.CCR-18-3190.
     PubMed     Abstract available
     
     
     
121. XIAO Y, Ma D, Zhao S, Suo C, et al
     Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer.
     Clin Cancer Res. 2019 Mar 5. pii: 1078-0432.CCR-18-3524.
     PubMed     Abstract available
     
     
     February 2019
122. DI COSIMO S, Appierto V, Pizzamiglio S, Tiberio P, et al
     Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial.
     Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2507.
     PubMed     Abstract available
     
     
     
123. CHUMSRI S, Serie DJ, Li Z, Pogue-Geile KL, et al
     Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
     Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2206.
     PubMed     Abstract available
     
     
     
124. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
     The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
     Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
     PubMed     Abstract available
     
     
     
125. LOI S, Dushyanthen S, Beavis PA, Salgado R, et al
     Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
     Clin Cancer Res. 2019;25:1437.
     PubMed    
     
     
     
126. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
     Correction: Association of FGFR1 with ERalpha Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER(+) Breast Cancer.
     Clin Cancer Res. 2019;25:1433.
     PubMed    
     
     
     
127. UNNI N, Sudhan DR, Arteaga CL
     Correction: Neratinib: Inching Up on the Cure Rate of HER2(+) Breast Cancer?
     Clin Cancer Res. 2019;25:1430.
     PubMed    
     
     
     
128. IIZUKA A, Nonomura C, Ashizawa T, Kondou R, et al
     A T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targets human breast cancer.
     Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-17-3123.
     PubMed     Abstract available
     
     
     
129. ZINGER L, Merenbakh-Lamin K, Klein Goldberg A, Elazar A, et al
     Ligand binding domain activating mutations of ESR1 rewire cellular metabolism of breast cancer cells.
     Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-1505.
     PubMed     Abstract available
     
     
     
130. MAYER IA, Prat A, Egle D, Blau S, et al
     A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
     Clin Cancer Res. 2019 Feb 5. pii: 1078-0432.CCR-18-3160.
     PubMed     Abstract available
     
     
     
131. NAKSHATRI H, Kumar B, Burney HN, Cox ML, et al
     Genetic ancestry-dependent differences in breast cancer-induced field defects in the tumor-adjacent normal breast.
     Clin Cancer Res. 2019 Feb 4. pii: 1078-0432.CCR-18-3427.
     PubMed     Abstract available
     
     
     January 2019
132. ELMI A, Makvandi M, Weng CC, Hou C, et al
     Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT.
     Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-2769.
     PubMed     Abstract available
     
     
     
133. TULOTTA C, Lefley DV, Freeman K, Gregory WM, et al
     Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.
     Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2202.
     PubMed     Abstract available
     
     
     
134. BERGEN ES, Berghoff AS, Medjedovic M, Rudas M, et al
     Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases.
     Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-1968.
     PubMed     Abstract available
     
     
     
135. CROSBY EJ, Gwin WR, Blackwell K, Marcom PK, et al
     Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study.
     Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-3102.
     PubMed     Abstract available
     
     
     
136. CLARK AS, McAndrew NP, Troxel A, Feldman M, et al
     Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.
     Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-0790.
     PubMed     Abstract available
     
     
     December 2018
137. HURVITZ SA, O'Shaughnessy J, Mason G, Yardley D, et al
     Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.
     Clin Cancer Res. 2018 Dec 28. pii: 1078-0432.CCR-18-2366.
     PubMed     Abstract available
     
     
     
138. TURNER NC, Telli ML, Rugo HS, Mailliez A, et al
     A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
     Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1891.
     PubMed     Abstract available
     
     
     
139. HWANG KT, Kim J, Jung J, Chang JH, et al
     Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database.
     Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-2782.
     PubMed     Abstract available
     
     
     
140. WILSON HE, Rhodes KK, Rodriguez D, Chahal I, et al
     Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue.
     Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-1565.
     PubMed     Abstract available
     
     
     
141. HOWIE LJ, Scher NS, Amiri-Kordestani L, Zhang L, et al
     FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer.
     Clin Cancer Res. 2018 Dec 14. pii: 1078-0432.CCR-18-3003.
     PubMed     Abstract available
     
     
     
142. MUNTASELL A, Rojo F, Servitja S, Rubio-Perez C, et al
     NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival.
     Clin Cancer Res. 2018 Dec 6. pii: 1078-0432.CCR-18-2365.
     PubMed     Abstract available
     
     
     November 2018
143. FOIDART P, Yip C, Radermacher J, Lienard M, et al
     Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy.
     Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-1880.
     PubMed     Abstract available
     
     
     
144. SHIINO S, Matsuzaki J, Shimomura A, Kawauchi J, et al
     Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer.
     Clin Cancer Res. 2018 Nov 27. pii: 1078-0432.CCR-18-1414.
     PubMed     Abstract available
     
     
     
145. MERIC-BERNSTAM F, Johnson A, Ileana Dumbrava EE, Raghav K, et al
     Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
     Clin Cancer Res. 2018 Nov 15. pii: 1078-0432.CCR-18-2275.
     PubMed     Abstract available
     
     
     
146. RACHNER TD, Kasimir-Bauer S, Gobel A, Erdmann K, et al
     Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in non-metastatic breast cancer.
     Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2482.
     PubMed     Abstract available
     
     
     
147. 
     Correction: Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
     Clin Cancer Res. 2018;24:5486.
     PubMed    
     
     
     
148. 
     Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.
     Clin Cancer Res. 2018;24:5485.
     PubMed    
     
     
     October 2018
149. WANG Z, Liu Q, Wilson CL, Easton J, et al
     Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE).
     Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1775.
     PubMed     Abstract available
     
     
     
150. GRELLETY T, Callens C, Richard E, Briaux A, et al
     Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target.
     Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1469.
     PubMed     Abstract available
     
     
     
151. VELDWIJK MR, Seibold P, Botma A, Helmbold I, et al
     Association of CD4(+) radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with >10-year follow-up.
     Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-0777.
     PubMed     Abstract available
     
     
     
152. CROESSMANN S, Formisano L, Kinch L, Gonzalez-Ericsson PI, et al
     Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
     Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-1544.
     PubMed     Abstract available
     
     
     
153. ABOUTALIB SS, Mohamed AA, Berg WA, Zuley ML, et al
     Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening.
     Clin Cancer Res. 2018 Oct 11. pii: 1078-0432.CCR-18-1115.
     PubMed     Abstract available
     
     
     September 2018
154. THOREK DL, Ku AT, Mitsiades N, Veach D, et al
     Harnessing Androgen-Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
     Clin Cancer Res. 2018 Sep 25. pii: 1078-0432.CCR-18-1521.
     PubMed     Abstract available
     
     
     
155. HENDERSON MC, Silver M, Tran Q, Letsios EE, et al
     A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment.
     Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0843.
     PubMed     Abstract available
     
     
     
156. CHEN X, Low KH, Alexander A, Jiang Y, et al
     Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.
     Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1446.
     PubMed     Abstract available
     
     
     August 2018
157. GUINDALINI RS, Zheng Y, Abe H, Whitaker K, et al
     Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
     Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-0200.
     PubMed     Abstract available
     
     
     
158. MEIJER TG, Verkaik NS, Sieuwerts AM, van Riet J, et al
     Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects.
     Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0063.
     PubMed     Abstract available
     
     
     
159. MENDEZ O, Peg V, Salvans C, Pujals M, et al
     Extracellular HMGA1 promotes tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
     Clin Cancer Res. 2018 Aug 22. pii: 1078-0432.CCR-18-0517.
     PubMed     Abstract available
     
     
     
160. TRAN TH, Utama FE, Sato T, Peck AR, et al
     Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling.
     Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-17-3280.
     PubMed     Abstract available
     
     
     
161. CHEUNG A, Opzoomer JW, Ilieva KM, Gazinska P, et al
     Anti-Folate Receptor alpha-directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer.
     Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0652.
     PubMed     Abstract available
     
     
     July 2018
162. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Khan QJ, et al
     Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.
     Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0585.
     PubMed     Abstract available
     
     
     
163. TANIOKA M, Fan C, Parker JS, Hoadley KA, et al
     Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer.
     Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-17-3431.
     PubMed     Abstract available
     
     
     
164. GONZALEZ-GONZALEZ A, Munoz-Muela E, Marchal JA, Cara FE, et al
     Activating transcription factor 4 modulates TGFbeta-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling.
     Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3125.
     PubMed     Abstract available
     
     
     June 2018
165. SHEN H, Mu C, Wu X, Zhou X, et al
     Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer.
     Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-17-3872.
     PubMed     Abstract available
     
     
     
166. CUI Y, Li B, Pollom EL, Horst K, et al
     Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
     Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0825.
     PubMed     Abstract available
     
     
     
167. PARK H, Lim Y, Ko ES, Cho HH, et al
     Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer.
     Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-3783.
     PubMed     Abstract available
     
     
     
168. SHAH D, Wyatt D, Baker A, Simms P, et al
     Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1.
     Clin Cancer Res. 2018 Jun 12. pii: 1078-0432.CCR-17-1952.
     PubMed     Abstract available
     
     
     
169. BARRY P, Vatsiou A, Spiteri I, Nichol D, et al
     The spatio-temporal evolution of lymph node spread in early breast cancer.
     Clin Cancer Res. 2018 Jun 11. pii: 1078-0432.CCR-17-3374.
     PubMed     Abstract available
     
     
     
170. BARDIA A, Hurvitz S
     Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.
     Clin Cancer Res. 2018 Jun 8. pii: 1078-0432.CCR-18-0162.
     PubMed     Abstract available
     
     
     May 2018
171. UNNI N, Sudhan DR, Arteaga CL
     Neratinib: Inching up on the cure rate of HER2+ breast cancer?
     Clin Cancer Res. 2018 May 25. pii: 1078-0432.CCR-18-1114.
     PubMed     Abstract available
     
     
     
172. ANURAG M, Punturi N, Hoog J, Bainbridge MN, et al
     Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers.
     Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-17-3702.
     PubMed     Abstract available
     
     
     
173. DICKLER MN, Saura C, Richards D, Krop I, et al
     Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
     Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-18-0613.
     PubMed     Abstract available
     
     
     
174. BAYRAKTAR R, Ivan C, Bayraktar E, Kanlikilicer P, et al
     Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion.
     Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-17-1959.
     PubMed     Abstract available
     
     
     April 2018
175. SPRING L, Bardia A
     Cycling Towards Progress: Ribociclib, CDK 4/6 inhibitor for Breast Cancer.
     Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0463.
     PubMed     Abstract available
     
     
     
176. VISSER LL, Elshof LE, Schaapveld M, Van de Vijver K, et al
     Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ - A nested case-control study.
     Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0201.
     PubMed     Abstract available
     
     
     
177. GOODMAN CR, Seagle BL, Kocherginsky M, Donnelly ED, et al
     21-gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1-2 N1 breast cancer.
     Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3169.
     PubMed     Abstract available
     
     
     
178. POST AEM, Smid M, Nagelkerke A, Martens JWM, et al
     Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer.
     Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-2551.
     PubMed     Abstract available
     
     
     
179. WEST DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, et al
     Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.
     Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2793.
     PubMed     Abstract available
     
     
     
180. LOIBL S, Weber K, Huober J, Krappmann K, et al
     Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor.
     Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-2947.
     PubMed     Abstract available
     
     
     
181. RUGO HS, Cortes J, Awada A, O'Shaughnessey J, et al
     Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.
     Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3059.
     PubMed     Abstract available
     
     
     March 2018
182. AFGHAHI A, Purington N, Han SS, Desai M, et al
     Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
     Clin Cancer Res. 2018 Mar 26. pii: 1078-0432.CCR-17-1323.
     PubMed     Abstract available
     
     
     
183. WARD E, Vareslija D, Charmsaz S, Fagan A, et al
     Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
     Clin Cancer Res. 2018 Mar 22. pii: 1078-0432.CCR-17-2615.
     PubMed     Abstract available
     
     
     
184. RUGO HS, Delord JP, Im SA, Ott PA, et al
     Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen ReceptorPositive/Human Epidermal Growth Factor Receptor 2Negative Advanced Breast Cancer.
     Clin Cancer Res. 2018 Mar 20. pii: 1078-0432.CCR-17-3452.
     PubMed     Abstract available
     
     
     
185. CHUMSRI S, Sperinde J, Liu H, Gligorov J, et al
     High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
     Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-1864.
     PubMed     Abstract available
     
     
     
186. FILIPITS M, Dafni U, Gnant M, Polydoropoulou V, et al
     Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.
     Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3473.
     PubMed     Abstract available
     
     
     
187. SINGH H, Walker AJ, Amiri-Kordestani L, Cheng J, et al
     U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.
     Clin Cancer Res. 2018 Mar 9. pii: 1078-0432.CCR-17-3628.
     PubMed     Abstract available
     
     
     
188. RICCIARDELLI C, Bianco-Miotto T, Jindal S, Butler LM, et al
     The Magnitude of Androgen Receptor Positivity in Breast Cancer is Critical for Reliable Prediction of Disease Outcome.
     Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-1199.
     PubMed     Abstract available
     
     
     
189. LIU L, Yang L, Yan W, Zhai J, et al
     Chemotherapy induces breast cancer stemness in association with dysregulated monocytosis.
     Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-2545.
     PubMed     Abstract available
     
     
     February 2018
190. FORMENTI SC, Lee P, Adams S, Goldberg JD, et al
     Focal Irradiation And Systemic Transforming Growth Factor beta Blockade in Metastatic Breast Cancer.
     Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-3322.
     PubMed     Abstract available
     
     
     
191. NEVEN P, Jongen L, Lintermans A, Van Asten K, et al
     Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial.
     Clin Cancer Res. 2018 Feb 19. pii: 1078-0432.CCR-17-3028.
     PubMed     Abstract available
     
     
     
192. KARAPANAGIOTIS S, Pharoah PDP, Jackson CH, Newcombe PJ, et al
     Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
     Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-3542.
     PubMed     Abstract available
     
     
     
193. HAMILTON EP, Patel MR, Armstrong AC, Baird RD, et al
     A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.
     Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-17-3102.
     PubMed     Abstract available
     
     
     
194. SHAH A, Bloomquist E, Tang S, Fu W, et al
     FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
     Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
     PubMed     Abstract available
     
     
     
195. KABRAJI S, Ni J, Lin N, Xie S, et al
     Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
     PubMed     Abstract available
     
     
     
196. MARTINS CD, Da Pieve C, Burley TA, Smith R, et al
     HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2754.
     PubMed     Abstract available
     
     
     
197. GONG C, Man EP, Tsoi H, Lee TK, et al
     BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer.
     Clin Cancer Res. 2018 Feb 2. pii: 1078-0432.CCR-17-2259.
     PubMed     Abstract available
     
     
     January 2018
198. MISHRA RR, Belder N, Ansari SA, Kayhan M, et al
     Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer.
     Clin Cancer Res. 2018 Jan 31. pii: 1078-0432.CCR-17-2776.
     PubMed     Abstract available
     
     
     
199. ECHAVARRIA I, Lopez-Tarruella S, Picornell AC, Garcia-Saenz JA, et al
     Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
     Clin Cancer Res. 2018 Jan 29. pii: 1078-0432.CCR-17-1912.
     PubMed     Abstract available
     
     
     
200. PIGGOTT L, da Silva AM, Robinson T, Santiago-Gomez A, et al
     Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
     Clin Cancer Res. 2018 Jan 23. pii: 1078-0432.CCR-17-1381.
     PubMed     Abstract available
     
     
     
201. YANG X, Pan Y, Qiu Z, Du Z, et al
     RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
     Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
     PubMed     Abstract available
     
     
     
202. MAGBANUA MJM, Rugo HS, Wolfe DM, Hauranieh L, et al
     Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.
     Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2312.
     PubMed     Abstract available
     
     
     
203. DAVILA-GONZALEZ D, Choi DS, Rosato RR, Granados-Principal S, et al
     Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.
     Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1437.
     PubMed     Abstract available
     
     
     December 2017
204. MASTORAKI S, Strati A, Tzanikou E, Chimonidou M, et al
     ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
     Clin Cancer Res. 2017 Dec 28. pii: 1078-0432.CCR-17-1181.
     PubMed     Abstract available
     
     
     
205. ZHAO EY, Shen Y, Pleasance E, Kasaian K, et al
     Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
     Clin Cancer Res. 2017;23:7521-7530.
     PubMed     Abstract available
     
     
     November 2017
206. LENZ G, Hamilton A, Geng S, Hong T, et al
     t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
     Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
     PubMed     Abstract available
     
     
     
207. ROSSI G, Mu Z, Rademaker A, Austin L, et al
     Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
     Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
     PubMed     Abstract available
     
     
     
208. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
     Novel predictors of breast cancer survival derived from miRNA activity analysis.
     Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
     PubMed     Abstract available
     
     
     
209. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
     A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
     Clin Cancer Res. 2017;23:6468-6477.
     PubMed     Abstract available
     
     
     October 2017
210. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
     Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
     Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
     PubMed     Abstract available
     
     
     
211. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
     Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
     Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
     PubMed     Abstract available
     
     
     
212. YU Z, He S, Wang D, Patel HK, et al
     Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
     Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
     PubMed     Abstract available
     
     
     September 2017
213. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
     Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
     Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
     PubMed     Abstract available
     
     
     
214. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
     PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
     Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
     PubMed     Abstract available
     
     
     
215. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
     Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
     Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
     PubMed     Abstract available
     
     
     
216. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
     A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
     Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
     PubMed     Abstract available
     
     
     
217. DIOT G, Metz S, Noske A, Liapis E, et al
     Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
     Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: